Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2023-04-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
年度募集资金使用鉴证报告
Regulatory Filings
2023-04-25 Chinese
2022年年度股东大会资料
AGM Information Classification · 100% confidence The document is titled as "2022 年年度股东大会资料" which translates to "2022 Annual General Meeting Materials." It contains detailed reports and proposals presented at the 2022 Annual General Meeting (AGM) of 特一药业集团股份有限公司 (Teyi Pharmaceutical Group Co., Ltd.). The content includes the Board of Directors' work report, Supervisory Board report, financial statements, audit opinions, and various proposals to be voted on at the AGM. The document is comprehensive and clearly intended as materials for the AGM rather than a standalone annual report or earnings release. Therefore, it fits the category of AGM Information (AGM-R).
2023-04-25 Chinese
2022年度独立董事述职报告（卢北京）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2022 by a specific independent director of the company. It details the director's attendance at board meetings, opinions on various company matters, committee work, investigations, supervision of information disclosure, and protection of shareholder rights. It is a narrative report on the director's activities and opinions rather than a financial report or announcement. It does not contain financial statements or earnings data, nor is it an announcement of voting results or a regulatory filing. The content fits best with a Board/Management Information report, which includes announcements or reports related to board members' activities and governance roles. The document length is under 5,000 characters, but it is a substantive report, not a mere announcement of a report publication. Therefore, the classification is MANG (Board/Management Information).
2023-04-25 Chinese
2022年年度审计报告
Regulatory Filings
2023-04-25 Chinese
公司章程修正案
Governance Information Classification · 95% confidence The document is titled as an amendment to the company's Articles of Association (公司章程修正案), detailing specific changes to the company's bylaws related to shareholder meeting authorities and board powers. It references regulatory provisions about stock issuance authorization and outlines specific clauses before and after amendment. The document is a formal announcement of proposed changes to the corporate governance documents, intended for shareholder approval at the next general meeting. It does not contain financial statements, audit information, or detailed financial results. It is not a full report but a governance-related announcement about changes to the company's internal rules. Therefore, the most appropriate classification is Governance Information (CGR). The document length is short and focused on governance amendments, not a report publication or regulatory filing. Confidence is high due to clear content and context.
2023-04-25 Chinese
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2022年度内部控制自我评价报告' which translates to '2022 Annual Internal Control Self-Evaluation Report' for 特一药业集团股份有限公司. It discusses the company's internal control evaluation for the fiscal year ending December 31, 2022, including governance structure, organizational structure, internal audit, risk management, and internal control deficiencies. The document is a detailed report on the company's internal control effectiveness and compliance with regulatory standards. It is not an announcement or a brief summary but a substantive report containing evaluation results and internal control assessments. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and internal control evaluations, distinct from full annual reports or other filings. The document length (6790 characters) and content confirm it is a full report rather than a short announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2022
2023-04-25 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.